Supplementary Table 1. Patient characteristics according to the levels of the maximum intima–media thickness of the carotid artery (Propensity score matched cohort: n = 38) .
| Variables | Entire Cohort | Max IMT ＜1.5 mm | Max IMT ≥ 1.5 mm | P -Value | SD |
|---|---|---|---|---|---|
| n = 38 | n = 19 | n = 19 | |||
| Clinical Findings | |||||
| Age (years) | 62.2±9.2 [38] | 61.8±10.4 | 62.5±8.2 | 0.8098 | 0.075 |
| Gender (Men; %) | 28 (73.7) [38] | 14 (73.7) | 14 (73.7) | 1.0000 | 0.000 |
| SBP (mmHg) | 126.0±7.1 [38] | 125.6±6.9 | 126.3±7.4 | 0.7821 | 0.098 |
| DBP (mmHg) | 77.6±5.4 [38] | 77.6±4.3 | 77.5±6.5 | 0.9454 | 0.018 |
| MBP (mmHg) | 93.7±5.8 [38] | 93.6±5.1 | 93.8±6.5 | 0.9438 | 0.034 |
| BMI (kg/m 2 ) | 25.1±3.6 [38] | 25.0±3.3 | 25.3±3.9 | 0.8210 | 0.083 |
| Max CCA-IMT (mm) | 0.9 (0.7–1.3) [38] | 0.8 (0.7–1.1) | 0.9 (0.8–1.8) | 0.0378 | 0.819 |
| Max bulb-IMT (mm) | 1.2 (0.9–1.9) [30] | 1.0 (0.9–1.3) | 1.8 (1.1–2.4) | 0.0028 | 1.176 |
| Max ICA-IMT (mm) | 1.8 (1.2–2.5) [25] | 1.2 (1.1–1.3) | 2.1 (1.7–3.4) | 0.0024 | 1.415 |
| Max IMT (mm) | 1.5 (1.2–2.4) [38] | 1.2 (0.9–1.3) | 2.4 (1.9–3.3) | ＜0.0001 | 2.026 |
| Distribution ratio of Max-IMT: CCA/ bulb /ICA | 6 (15.8)/ 13 (34.2)/ 19 (50.0) | 4 (21.1)/ 9 (47.4)/ 6 (31.6) | 2 (10.5)/ 4 (21.1)/ 13 (68.4) | 0.0754 | NA |
| Laboratory Findings | |||||
| Serum Albumin (g/dL) | 4.23±0.30 [38] | 4.17±0.33 | 4.29±0.26 | 0.2174 | 0.404 |
| Hemoglobin (g/dL) | 14.1±1.5 [38] | 14.1±1.7 | 14.2±1.3 | 0.9573 | 0.066 |
| Serum Creatinine (mg/dL) | 0.97±0.24 [38] | 0.97±0.25 | 0.97±0.24 | 0.9372 | 0.000 |
| eGFR (mL/min/1.73 m 2 ) | 61.0±16.7 [38] | 61.3±16.5 | 60.7±17.3 | 0.9133 | 0.035 |
| CKD stage 1/ 2/ 3a/3b/4/5 (%) |
2 (5.3)/ 15 (39.5)/ 16 (42.1)/ 5 (13.2)/ 0 (0.0)/ 0 (0.0) |
1 (5.3)/ 7 (36.8)/ 9 (47.4)/ 2 (10.5)/ 0 (0.0)/ 0 (0.0) |
1 (5.3)/ 8 (42.1)/ 7 (36.8)/ 3 (15.8)/ 0 (0.0)/ 0 (0.0) |
0.9152 | NA |
| Uric Acid (mg/dL) | 6.17±1.28 [38] | 6.22±1.48 | 6.11±1.08 | 0.7935 | 0.085 |
| Triglyceride (mg/dL) | 141.3±64.0 [38] | 125.1±55.2 | 157.5±69.4 | 0.1203 | 0.517 |
| Total Cholesterol (mg/dL) | 207.3±33.9 [38] | 202.6±31.7 | 211.9±36.2 | 0.4069 | 0.273 |
| LDL Cholesterol (mg/dL) | 123.8±33.8 [38] | 120.6±35.0 | 127.0±33.2 | 0.5631 | 0.188 |
| HDL Cholesterol (mg/dL) | 55.6±12.9 [38] | 57.1±12.5 | 54.2±13.5 | 0.4979 | 0.223 |
| Glucose (mg/dL) | 108.6±27.7 [38] | 112.1±24.6 | 105.0±30.7 | 0.4366 | 0.255 |
| Hemoglobin A1c (NGSP) (%) | 6.05±0.69 [38] | 6.11±0.78 | 5.99±0.59 | 0.6265 | 0.174 |
| Hs-CRP (ng/mL) | 412.0 (246.0–680.5) [37] | 473.0 (301.3–714.0) | 402.0 (219.0–620.0) | 0.5740 | 0.166 |
| UACR (mg/g Cre) | 40.3 (18.0–148.3) [38] | 42.1 (18.6–150.4) | 34.8 (17.5–147.0) | 0.8040 | 0.253 |
| Primary cause of CKD | |||||
| Diabetic nephropathy (%) | 2 (5.3) [38] | 1 (5.3) | 1 (5.3) | 1.0000 | 0.000 |
| Chronic glomerulonephritis (%) | 18 (47.4) [38] | 7 (36.8) | 11 (57.9) | 0.3300 | 0.432 |
| Nephrosclerosis (%) | 12 (31.6) [38] | 8 (42.1) | 4 (21.1) | 0.2953 | 0.464 |
| Others (%) | 6 (15.8) [38] | 3 (15.8) | 3 (15.8) | 1.0000 | 0.000 |
| Concomitant drugs | |||||
| Antihypertensive agents (%) | 26 (68.4) [38] | 12 (63.2) | 14 (73.7) | 0.7281 | 0.227 |
| ARB and or ACEI | 18 (47.4) [38] | 8 (42.1) | 10 (52.6) | 0.7459 | 0.211 |
| CCB | 9 (23.7) [38] | 4 (21.1) | 5 (26.3) | 1.0000 | 0.123 |
| Antidyslipidemic agents ( n (%)) | 16 (42.1) [38] | 7 (36.8) | 9 (47.4) | 0.7431 | 0.216 |
| Antihyperuricemic agents (%) | 17 (44.7) [38] | 12 (63.2) | 5 (26.3) | 0.0489 | 0.799 |
| Antidiabetic agents (%) | 5 (13.2) [38] | 2 (10.5) | 3 (15.8) | 1.0000 | 0.157 |
| Corticosteroids (%) | 5 (13.2) [38] | 3 (15.8) | 2 (10.5) | 1.0000 | 0.157 |
| Immunosuppressants (%) | 3 (7.9) [38] | 2 (10.5) | 1 (5.3) | 1.0000 | 0.194 |
| Diuretics (%) | 9 (23.7) [38] | 5 (26.3) | 4 (21.1) | 1.0000 | 0.123 |
| Comorbidities | |||||
| Hypertension (%) | 26 (68.4) [38] | 12 (63.2) | 14 (73.7) | 0.7281 | 0.227 |
| Hyperuricemia (%) | 22 (57.9) [38] | 14 (73.7) | 8 (42.1) | 0.0991 | 0.676 |
| Hypertriglyceridemia (%) | 22 (57.9) [38] | 9 (47.4) | 13 (68.4) | 0.3245 | 0.435 |
| Hypercholesterolemia (%) | 25 (65.8) [38] | 10 (52.6) | 15 (79.0) | 0.1704 | 0.579 |
| Low HDL cholesterol (%) | 18 (47.4) [38] | 7 (36.8) | 11 (57.9) | 0.3300 | 0.432 |
| Hyperglycemia (%) | 22 (57.9) [38] | 14 (73.7) | 8 (42.1) | 0.0991 | 0.676 |
| Diabetes mellitus (%) | 8 (21.1) [38] | 4 (21.1) | 4 (21.1) | 1.0000 | 0.000 |
＊ Continuous variables are expressed as means and standard deviations. Categorical variables are expressed as n (%). Values of nonmissing data are shown in [ ]. Abbreviations: Max IMT, maximum measurable intima-media thickness in the entire scanned common carotid arteries, carotid bulbs, and internal carotid arteries; n , number; P , calculated probability; SD, standardized differences; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; BMI, body mass index; Max CCA-IMT, maximum intima–media thickness of the common carotid artery; Max bulb-IMT, maximum intima–media thickness of the carotid bulb; Max ICA-IMT, maximum intima–media thickness of the internal carotid artery; NA, not applicable; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; LDL, low-density lipoprotein; HDL, high- density lipoprotein; Hs-CRP, high sensitivity C-reactive protein; UACR, urine albumin-to-creatinine ratio; ARB, angiotensin Ⅱ receptor blocker; ACEI, angiotensin converting enzyme inhibitor; CCB, calcium-channel blocker.